Detalhe da pesquisa
1.
Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome.
Mol Med
; 27(1): 48, 2021 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33975537
2.
High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome.
Mol Med
; 20: 538-47, 2015 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25247290
3.
Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome.
Mol Med
; 26(1): 131, 2020 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33380314
4.
Expression of concern to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome.
Mol Med
; 26(1): 17, 2020 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32013863
5.
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
PLoS One
; 18(12): e0295838, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38157348
6.
Immunoprofiling of active and inactive systemic juvenile idiopathic arthritis reveals distinct biomarkers: a single-center study.
Pediatr Rheumatol Online J
; 19(1): 173, 2021 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34963488
7.
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Arthritis Res Ther
; 20(1): 285, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587248